Fat in the liver and insulin resistance (Q36265235)

13 August 2017

1 reference

title

Fat in the liver and insulin resistance (English)

1 reference

13 August 2017

1 reference

1

Hannele Yki-Järvinen

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

37

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

347-356

1 reference

13 August 2017

cites work

Lipoatrophy revisited

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Metabolic lessons from genetically lean mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Life without white fat: a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Metabolic and nutritional considerations in nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Splanchnic lipolysis in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

The case of visceral fat: argument for the defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Fat distribution, lipid accumulation in the liver, and exercise capacity do not explain the insulin resistance in healthy males with a family history for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Obesity is associated with macrophage accumulation in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Association between Diabetes and Elevated Serum Alanine Aminotransferase Activity among Mexican Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Gamma-glutamyltransferase and diabetes--a 4 year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Diabetes increases the risk of acute hepatic failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Obesity and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Dietary fat content modifies liver fat in overweight nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

Prospective Study of Serum -Glutamyltransferase and Risk of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/07853890510037383

10.1080/07853890510037383

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference